182 related articles for article (PubMed ID: 29041854)
1. [Not Available].
Bywater M; Kessler TM
Praxis (Bern 1994); 2017; 106(21):1175-1181. PubMed ID: 29041854
[No Abstract] [Full Text] [Related]
2. [Not Available].
Perucchini D; Betschart C; Fink D; Scheiner DA
Praxis (Bern 1994); 2017 Jan; 106(1):37-44. PubMed ID: 28055318
[No Abstract] [Full Text] [Related]
3. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
[TBL] [Abstract][Full Text] [Related]
5. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of female overactive bladder syndrome and treatment-related effects.
Hsiao SM; Lin HH
J Formos Med Assoc; 2018 Oct; 117(10):871-878. PubMed ID: 29398096
[TBL] [Abstract][Full Text] [Related]
7. Understanding clinic options for overactive bladder.
Bartley JM; Blum ES; Sirls LT; Peters KM
Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
[TBL] [Abstract][Full Text] [Related]
8. Actual treatment of overactive bladder and urge urinary incontinence.
Cornu JN
Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
[TBL] [Abstract][Full Text] [Related]
9. [Overactive bladder-which treatment when?].
Pannek J
Urologe A; 2017 Dec; 56(12):1532-1538. PubMed ID: 29043374
[TBL] [Abstract][Full Text] [Related]
10. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for overactive bladder.
Karmarkar R; Khullar V
Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
[TBL] [Abstract][Full Text] [Related]
12. New treatments for incontinence.
MacLachlan LS; Rovner ES
Adv Chronic Kidney Dis; 2015 Jul; 22(4):279-88. PubMed ID: 26088072
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
[TBL] [Abstract][Full Text] [Related]
14. Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies.
Ginsberg DA; Schneider LK; Watanabe TK
Arch Phys Med Rehabil; 2015 Sep; 96(9 Suppl):S341-57.e1. PubMed ID: 26318392
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Nonsurgical Treatments of Overactive Bladder in the United States.
Brucker BM; Lee RK; Newman DK
Urology; 2020 Nov; 145():52-59. PubMed ID: 32598892
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Con.
Siegel S
J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742452
[No Abstract] [Full Text] [Related]
19. Real World Performance of Sacral Neuromodulation and OnabotulinumtoxinA for Overactive Bladder: Focus on Safety and Cost.
Chughtai B; Clemens JQ; Thomas D; Sun T; Ghomrawi H; Sedrakyan A
J Urol; 2020 Jan; 203(1):179-184. PubMed ID: 31347949
[TBL] [Abstract][Full Text] [Related]
20. Overactive bladder - 18 years - Part II.
Truzzi JC; Gomes CM; Bezerra CA; Plata IM; Campos J; Garrido GL; Almeida FG; Averbeck MA; Fornari A; Salazar A; Dell'Oro A; Cintra C; Sacomani CA; Tapia JP; Brambila E; Longo EM; Rocha FT; Coutinho F; Favre G; Garcia JA; Castano J; Reyes M; Leyton RE; Ferreira RS; Duran S; Lopez V; Reges R
Int Braz J Urol; 2016; 42(2):199-214. PubMed ID: 27176185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
